Ireland
--:--IST
Recruiting Not applicable

Improving Health Outcomes With Kefir

NCT06695221 · tracked via the Priya Life Science Canada tracker
Phase
Not applicable
Started
2026-03-24
Last updated
2026-05-08

Condition(s) studied

Systemic Inflammatory ResponseDiabetes Mellitus, Type 2Cardiovascular Diseases

Investigational drug(s) / intervention(s)

Traditional KefirMilk (placebo)

Traditional Kefir: 350 mL/day of traditional fermented/prepared kefir

Milk (placebo): 350 mL/day of commercial 2% fat milk

Study summary

The purpose of the study is to ascertain whether traditional kefir not only enhances vascular health but also contributes to improved immune outcomes in both male and female participants at higher risk or living with Type 2 Diabetes (T2D) after 12 weeks of treatment.

Eligibility

Sex
ALL
Min age
24 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria: 1. females and males (24-70 years old) living in Edmonton (or Edmonton area/driving distance); 2. overweight or obesity (BMI \>25 Caucasian, \>23 Asian); 3. at higher risk of T2D (fasting blood glucose ≥ 5.6 - 6.9 mmol/L or/and HbA1C ≥ 5.5 - 6.4%); or 4. with diagnosis of T2D (fasting blood glucose ≥ 7.0 mmol/L or/and HbA1C ≥ 6.5%). Exclusion Criteria: 1. a usual high intake (maximum intake 3 servings/week) of fermented foods excluding cheese (i.e., kefir, kombucha, kimchi, etc.) for the past 3 months; 2. gastrointestinal (GI) disorders of any kind; 3. being pregnant or breastfeeding; 4. monogenic dyslipidemias and endocrine disorders except for diabetes; 5. use of medications within the last 3 months (i.e., antibiotics or antifungals, corticosteroids, methotrexate, or immunosuppressive cytotoxic agents); 6. any health conditions deemed to interfere with primary outcomes at the investigator's discretion (e.g., kidney disease, liver disease, cancer, GI surgery, heavy alcohol consumption, etc.); 7. having a pacemaker or any electrical medical device that prevents the individual from undergoing the bioelectrical impedance analysis bioimmunoassay (BIA) test."

Primary outcome measure(s)

  • Change in Glycated Hemoglobin (HbA1c) Levels (Percentage) — Baseline, 6 weeks, 12 weeks
    The primary outcome is the change in HbA1c levels, measured as a percentage of total hemoglobin using standard laboratory methods. This measurement assesses average blood glucose levels over the past 2-3 months, providing insight into the effect of our traditional kefir on long-term glucose regulation.

Trial sites (1)

FacilityCityRegionStatus
University of Alberta Edmonton Alberta Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06695221 on ClinicalTrials.gov ↗ ← All trials in Canada